Al-Ola Abdallah: Early Daratumumab Improved Progression-free and Overall Survival in High-risk SMM

Coverage, in order

1. 3d ago
   
   OncoDaily obscure study

   Al-Ola Abdallah: Early Daratumumab Improved Progression-free and Overall Survival in High-risk SMM

   Al-Ola Abdallah, Director of Plasma Cell Disorders Care at The University of Kansas Health System and Chair of USMIRC, shared Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.